Sunitinib is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
Sunitinib is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC).
Sunitinib is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
Sunitinib is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.
from FDA,2021.08
Lucius Version of Sunitinib: Dosage and Administration, Indications, Precautions···【more】
Release date:2025-12-01Recommended:14